9e1a43acfd
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
- Source: inbox/queue/2026-05-07-pmc-glp1-psychiatric-systematic-review-2026.md - Domain: health - Claims: 2, Entities: 0 - Enrichments: 5 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
18 lines
2 KiB
Markdown
18 lines
2 KiB
Markdown
---
|
|
type: claim
|
|
domain: health
|
|
description: Pharmacovigilance data shows odds ratios of 4.45 for concurrent antidepressant use and 4.07 for benzodiazepines, creating an underappreciated drug-drug interaction risk
|
|
confidence: experimental
|
|
source: Sa et al. (2026), systematic review of 38 studies with pharmacovigilance analysis
|
|
created: 2026-05-07
|
|
title: GLP-1 receptor agonists quadruple suicidal ideation risk when combined with antidepressants or benzodiazepines
|
|
agent: vida
|
|
sourced_from: health/2026-05-07-pmc-glp1-psychiatric-systematic-review-2026.md
|
|
scope: causal
|
|
sourcer: Sa et al. (2026)
|
|
related: ["human-in-the-loop-clinical-ai-degrades-to-worse-than-ai-alone", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations"]
|
|
---
|
|
|
|
# GLP-1 receptor agonists quadruple suicidal ideation risk when combined with antidepressants or benzodiazepines
|
|
|
|
Pharmacovigilance analysis within this systematic review identified elevated suicidal ideation odds ratios of 4.45 when GLP-1 receptor agonists are used concurrently with antidepressants, and 4.07 for concurrent benzodiazepine users. This represents a clinically significant drug-drug interaction that is structurally underdetected because GLP-1 prescribers in primary care may not have visibility into patients' psychiatric medication lists. The review notes that 'most RCTs excluded individuals with active suicidality or moderate-to-severe mood disorders — the population most at psychiatric risk,' meaning the interaction signal emerges from real-world pharmacovigilance rather than controlled trials. The authors recommend 'special caution for psychotropic medication co-users' but no formal contraindication or dose adjustment protocol exists. This creates a monitoring gap where the highest-risk population (those already on psychiatric medications) receives GLP-1 therapy without systematic psychiatric oversight.
|